Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal

| From

SAN MARINO, Calif., Sept. 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine that may succeed where small molecules and proteins have failed. Noted for its recent demonstrations of safety and single-agent efficacy in several types of metastatic cancers that were refractory to standard chemotherapy, Rexin-G is described as the world's second commercially approved gene therapy-while it remains the first and so far only targeted, injectable genetic medicine that has been effectively validated in the clinic.

EPEIUSRexin-G, with its elegant tumor-targeting biotechnologies, performs a vital surveillance function for the benefit of the cancer patient: distributing throughout the general circulation, while constantly seeking-out and accumulating in primary tumors and metastatic tissues that have spread throughout the body. Within minutes, the tumor-targeted nanoparticles of Rexin-G begin to accumulate within the cancerous lesions to high levels, delivering a lethal payload of genetic medicine selectively to cancer cells and their attendant blood supply, while sparing normal cells and tissues.

In a series of four clinical trials that are currently ongoing in the United States, Rexin-G has demonstrated dose-dependent improvements in tumor-control indices, while exhibiting no dose-limiting toxicities. The JNCI article noted that Rexin-G has been granted Orphan Drug Status by the U.S. FDA for three different types of cancers: osteosarcoma, soft-tissue sarcoma, and pancreatic cancer. Ten months ago, Rexin-G was formally approved in the Philippines for the treatment of all solid tumors that are refractory to standard chemotherapies.

The JNCI NEWS article also highlighted the second tumor-targeted agent in development by Epeius Biotechnologies, describing Reximmune-C as an immune stimulant, or personalized cancer vaccine, designed to be used alone or in combination with Rexin-G. Reximmune-C incorporates a powerful cytokine gene, in place of the cytocidal gene used in Rexin-G, to deliver an immune-stimulating pulse to activate a patient's own immune cells in the area of residual tumors to prevent recurrence. Remarkably, several of the prominent cancer researchers, companies, and academicians interviewed for the JNCI article focused-in principle-on the very same issues that Epeius Biotechnologies, with its definitive molecular engineering platform, has actually managed to address. The JNCI article is well worth reading.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. To learn more about our pipeline of proprietary biotechnologies that are currently available for licensing and clinical development, please visit our website,

For more information about Rexin-G, Reximmune-C, and on-going clinical trials in the USA and abroad, please contact Dr. Erlinda M. Gordon at

All trademarks acknowledged.

News Source:
Like, Share, Save this press release:
  TWEET   SHARE   G+   STUMBLE   LinkedIn   Instapaper   Buffer

The content of the above press release was provided by the “news source” (Epeius Biotechnologies Corporation) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2008 Epeius Biotechnologies Corporation with newswire version Copr. © 2008 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Oct 27 2016:
[ count retired 8.4.16 ]

Drugs and Pharmaceuticals, Business, or: Search

back to top
REFERENCES: Epeius Biotechnologies, metastatic cancer drugs, Epeius Biotechnologies Corporation, Erlinda M. Gordon, M.D., biopharmaceutical company dedicated to the advancement of genetic medicine, Reximmune-C as an immune stimulant, Rexin-G, metastatic cancer drugs, news, press release from Epeius Biotechnologies Corporation, Sep 15, 2008, Drugs and Pharmaceuticals, , , , , Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal